Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Roche Finally Start Combination Melanoma Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.
Advertisement

Related Content

Tandem Approval Brings GSK’s Tafinlar And Mekinist To A Market Ready To Test Combinations
Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
Speedy Approval Of Roche's Zelboraf Puts Pressure On Bristol's Yervoy
Front-Line Of Melanoma Market Could Be Marketing Battle
First-Line Market For Melanoma Not A Lock For Bristol Or Roche
Roche's Vemurafenib Filed With Companion Diagnostic In Tow
Beyond The Guidance: The Business Of Co-Development Combinations
Yervoy Approval Has Shifted Development Landscape For Melanoma
Yervoy Approval Has Shifted Development Landscape For Melanoma

Topics

Advertisement
UsernamePublicRestriction

Register

PS072385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel